Entrada Therapeutics, Inc. (TRDA)
Market Cap | 519.76M |
Revenue (ttm) | 162.87M |
Net Income (ttm) | 23.49M |
Shares Out | 37.13M |
EPS (ttm) | 0.64 |
PE Ratio | 21.88 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 58,599 |
Open | 14.36 |
Previous Close | 14.32 |
Day's Range | 13.98 - 14.53 |
52-Week Range | 10.75 - 18.44 |
Beta | -0.23 |
Analysts | Strong Buy |
Price Target | 21.00 (+50.0%) |
Earnings Date | Aug 6, 2024 |
About TRDA
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and E... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TRDA stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 50.00% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/o/u/press16-2492435.jpg)
Entrada Therapeutics Announces $100 Million Registered Direct Offering
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healt...
![](https://cdn.snapi.dev/images/v1/3/c/press11-2492299.jpg)
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physic...
![](https://cdn.snapi.dev/images/v1/e/b/conf15-2458527.jpg)
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class ...
![](https://cdn.snapi.dev/images/v1/m/l/conf20-2434300.jpg)
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class o...
![](https://cdn.snapi.dev/images/v1/t/z/press11-2414195.jpg)
Entrada Therapeutics Reports First Quarter 2024 Financial Results
– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –
![](https://cdn.snapi.dev/images/v1/f/h/press16-2321772.jpg)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 ...
![](https://cdn.snapi.dev/images/v1/e/1/conf17-2264040.jpg)
Entrada Therapeutics to Present at Upcoming Investor Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular ...
![](https://cdn.snapi.dev/images/v1/y/m/press13-2201192.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advi...
![](https://cdn.snapi.dev/images/v1/j/w/press4-2168512.jpg)
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second hal...
![](https://cdn.snapi.dev/images/v1/t/i/press12-2072354.jpg)
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
– Initiation of Phase 1 clinical trial marks Entrada's transition into a clinical company – – Data anticipated in the second half of 2024 – BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeut...
![](https://cdn.snapi.dev/images/v1/x/a/press17-2016734.jpg)
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
![](https://cdn.snapi.dev/images/v1/b/g/press7-2011446.jpg)
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –
![](https://cdn.snapi.dev/images/v1/9/k/conf1-1922290.jpg)
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosoma...
![](https://cdn.snapi.dev/images/v1/e/q/press1-1881777.jpg)
Entrada Therapeutics Reports First Quarter 2023 Financial Results
- $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 -
![](https://cdn.snapi.dev/images/v1/q/o/press10-1824576.jpg)
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Esca...
![](https://cdn.snapi.dev/images/v1/i/v/press12-1816622.jpg)
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Esca...
![](https://cdn.snapi.dev/images/v1/z/f/press16-1783137.jpg)
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
- Established a transformative collaboration with Vertex to discover and develop intracellular Endosomal Escape Vehicle-therapeutics for myotonic dystrophy type 1 -
![](https://cdn.snapi.dev/images/v1/m/q/press1-1771730.jpg)
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world's foremost intracellular the...
![](https://cdn.snapi.dev/images/v1/s/h/press6-1741302.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
NEW YORK , Feb. 7, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advis...
![](https://cdn.snapi.dev/images/v1/b/t/press3-1699484.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such in...
![](https://cdn.snapi.dev/images/v1/l/a/press19-1681208.jpg)
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...
![](https://cdn.snapi.dev/images/v1/j/o/biotech22-1667829.jpg)
Entrada Therapeutics shares jump on collaboration with Vertex
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop trea...
![](https://cdn.snapi.dev/images/v1/n/p/press18-1667600.jpg)
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced a global collaboration focused on discovering and developing...
![](https://cdn.snapi.dev/images/v1/w/k/press19-1621862.jpg)
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 4...
![](https://cdn.snapi.dev/images/v1/g/h/conf19-1523810.jpg)
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap...